These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22440585)

  • 1. Analysing stratified medicine business models and value systems: innovation-regulation interactions.
    Mittra J; Tait J
    N Biotechnol; 2012 Sep; 29(6):709-19. PubMed ID: 22440585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
    Fugel HJ; Nuijten M; Postma M
    N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regenerative medicine: learning from past examples.
    Couto DS; Perez-Breva L; Cooney CL
    Tissue Eng Part A; 2012 Nov; 18(21-22):2386-93. PubMed ID: 22697402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries.
    Mittra J; Tait J; Wield D
    Trends Biotechnol; 2011 Mar; 29(3):105-9. PubMed ID: 21163543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can open-source drug R&D repower pharmaceutical innovation?
    Munos B
    Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The business of emergency medicine: a model for success.
    Proctor J; Hall P; Carr J
    Emerg Med Clin North Am; 2004 Feb; 22(1):19-45. PubMed ID: 15062495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value captor's process: getting the most out of your new business ventures.
    McGrath RG; Keil T
    Harv Bus Rev; 2007 May; 85(5):128-36, 146. PubMed ID: 17494256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges for pharmaceutical industry: new partnerships for sustainable human health.
    Hunter J
    Philos Trans A Math Phys Eng Sci; 2011 May; 369(1942):1817-25. PubMed ID: 21464073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brazil: An emerging partner in drug R&D.
    Rodrigues DG
    IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovation in industry and the diffusion of technology.
    Utterback JM
    Science; 1974 Feb; 183(4125):620-6. PubMed ID: 17778831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells.
    Mittra J; Tait J; Mastroeni M; Turner ML; Mountford JC; Bruce K
    N Biotechnol; 2015 Jan; 32(1):180-90. PubMed ID: 25094050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of Human Health Discoveries. 10 years results of Young Innovative Company incubation].
    Marsac J
    Bull Acad Natl Med; 2014; 198(4-5):905-16. PubMed ID: 26753415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategy as ecology.
    Iansiti M; Levien R
    Harv Bus Rev; 2004 Mar; 82(3):68-78, 126. PubMed ID: 15029791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem.
    Banda G; Tait J; Mittra J
    Clin Ther; 2018 Jul; 40(7):1084-1094. PubMed ID: 30017170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.